Dr. David Sommerhalder
Hematology & Oncology (Hematology & Oncology Physician)
- Medicare participating
At a glance
- Years since graduation
- 13
- In the NPI registry since
- 2014
- Medicare patients seen, 2024
- 124
Licensed in Texas since 2020, according to the Texas Medical Board. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2014Registered with an NPI (national billing number; not a license date)
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
TX license S5270 (first issued 2020; active) -
Internal Medicine Physician
TN license S5270 - Student in an Organized Health Care Education/Training Program
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Methodist Hospital San Antonio, TX
Medical groups
- Texas Oncology PA (1,014 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 124
- Services billed
- 24,736
- Patients’ average age
- 71
| Service | Times | Patients |
|---|---|---|
| Injection, palonosetron hcl, 25 mcg | 310 | 13 |
| Established patient office or other outpatient visit, 20-29 minutes | 264 | 82 |
| Injection, granisetron hydrochloride, 100 mcg | 210 | 15 |
| Established patient office or other outpatient visit, 30-39 minutes | 199 | 72 |
| Administration of chemotherapy into vein, 1 hour or less | 147 | 43 |
| Infusion into a vein for hydration, each additional hour | 85 | 24 |
| Injection of additional new drug or substance into vein | 77 | 23 |
| Infusion, normal saline solution , 1000 cc | 62 | 22 |
| Infusion into a vein for hydration, 31-60 minutes | 53 | 22 |
| Injection of drug or substance into vein | 41 | 20 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Levothyroxine Sodium Other prescribers in San Antonio, TX | 44 |
| Prednisone Other prescribers in San Antonio, TX | 41 |
| Gabapentin Other prescribers in San Antonio, TX | 31 |
| Doxycycline Monohydrate Other prescribers in San Antonio, TX | 24 |
| Granisetron Hcl | 24 |
| Eliquis (apixaban) Other prescribers in San Antonio, TX | 22 |
| Xtandi (enzalutamide) | 22 |
| Hydrocodone-Acetaminophen (hydrocodone/acetaminophen) Other prescribers in San Antonio, TX | 21 |
| Trazodone Hcl Other prescribers in San Antonio, TX | 19 |
| Abiraterone Acetate | 19 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 25 companies reported 57 payments worth $1,924 in total to this clinician.
| Siemens Medical Solutions USA, Inc. | $460 |
|---|---|
| Novartis Pharmaceuticals Corporation | $193 |
| Caris Mpi, Inc. | $137 |
| AbbVie Inc. | $125 |
| Regeneron Healthcare Solutions, Inc. | $124 |
| Daiichi Sankyo Inc. | $102 |
| Astellas Pharma US Inc | $99.99 |
| Lilly USA, LLC | $83.13 |
| Food and Beverage | $1,364 |
|---|---|
| Consulting Fee | $460 |
| Education | $99.99 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Siemens Medical Solutions USA, Inc. Jan 22, 2025 | Consulting Fee ARIA Radiation Therapy Management Software · Oncology | $460 |
| Astellas Pharma US Inc Jun 9, 2025 | Education in-kind | $99.99 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 28 industry-funded studies in 2025, from 13 companies. The companies reported $2,396,217 in research payments for these studies, mostly to the institutions running them.
- A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Patients with Advanced Solid Tumors
Exelixis Inc. - A Phase 1 Open Label Multiple Dose Dose Escalation and Expansion Study to Investigate the Safety Tolerability Pharmacokinetics and Antitumor Activity of the PTK7-Targeted Antibody-drug Conjugate DAY301 in Patients Wit…
Day One Biopharmaceuticals - Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
AbbVie Inc. · Recruiting · NCT05005403 - A Phase 1 First-in-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of AMG 355 as Monotherapy and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors
Amgen Inc. - Phase 1 Dose-Escalation Study of XB628 in Recurrent Advanced or Metastatic Solid Tumors
Exelixis Inc. - A Phase 1/1b Trial of MRTX849 in Combination With Palbociclib in Patients With Advanced Solid Tumors With KRAS G12C Mutation
E.r. Squibb & Sons, L.l.c. - A Phase 1/1b First- in -Human Trial of BMS-986484 as Monotherapy and in Combination Therapies in Participants with Advanced Solid Malignancies
E.r. Squibb & Sons, L.l.c. - A phase 1/2 first-time-in-human, open-label, multicenter, dose escalat
GlaxoSmithKline, LLC. - A phase 1 clinical study to evaluate the safety, tolerability, pharmac
GlaxoSmithKline, LLC. - A phase 1 dose escalation and expansion study to evaluate safety tolerability pharmacokinetic pharmacodynamic and antitumor activity of PF07248144 in participants with advanced or metastatic solid tumors
Pfizer Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.